Literature DB >> 18610582

[Adeno-associated viruses (AAV)].

Maciej Małecki1, Agnieszka Woźniak, Przemysław Janik.   

Abstract

Recombinant adeno-associated virus derived vectors (rAAV) a thought to be a most promising candidates for gene therapy applications. Their nonpathogenic nature as well as the encouraging capability to infect both proliferating and non proliferating cells are advantages for gene therapy applications. Here, we summarize the potential mechanisms responsible for AAV maintenance and site-specific integration to human genome. The role of Rep proteins, inverted terminal repeats and p5 promotor sequences for chromosomal incorporation of AAV are discussed. Making the site-specific integrative recombinant AAV vectors for gene therapy seems to be closely dependent on the development of viral vectorology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18610582

Source DB:  PubMed          Journal:  Postepy Biochem        ISSN: 0032-5422


  1 in total

1.  Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells.

Authors:  Maciej Malecki; Robert Proczka; Joanna Chorostowska-Wynimko; Paweł Swoboda; Anna Delbani; Jan Pachecka
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.